Cargando…

Risk-benefit of AstraZeneca COVID-19 vaccination in Australia

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8642228/
http://dx.doi.org/10.1007/s40278-021-06332-8
_version_ 1784609648729391104
collection PubMed
description
format Online
Article
Text
id pubmed-8642228
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-86422282021-12-06 Risk-benefit of AstraZeneca COVID-19 vaccination in Australia Reactions Weekly Clinical Study Springer International Publishing 2021-12-04 2021 /pmc/articles/PMC8642228/ http://dx.doi.org/10.1007/s40278-021-06332-8 Text en © Springer International Publishing AG 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Clinical Study
Risk-benefit of AstraZeneca COVID-19 vaccination in Australia
title Risk-benefit of AstraZeneca COVID-19 vaccination in Australia
title_full Risk-benefit of AstraZeneca COVID-19 vaccination in Australia
title_fullStr Risk-benefit of AstraZeneca COVID-19 vaccination in Australia
title_full_unstemmed Risk-benefit of AstraZeneca COVID-19 vaccination in Australia
title_short Risk-benefit of AstraZeneca COVID-19 vaccination in Australia
title_sort risk-benefit of astrazeneca covid-19 vaccination in australia
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8642228/
http://dx.doi.org/10.1007/s40278-021-06332-8